The nuclear eicosanoid receptor, PPARgamma, is aberrantly expressed in colonic cancers
about
Therapeutic potential of peroxisome proliferator-activated receptors in chronic inflammation and colorectal cancer.The non-genomic crosstalk between PPAR-gamma ligands and ERK1/2 in cancer cell linesPPARgamma-independent induction of growth arrest and apoptosis in prostate and bladder carcinomaPeroxisome proliferator-activated receptor gamma and spermidine/spermine N1-acetyltransferase gene expressions are significantly correlated in human colorectal cancerCyclooxygenase-dependent signalling: molecular events and consequences.Lymphovascular and neural regulation of metastasis: shared tumour signalling pathways and novel therapeutic approaches.Dynamics of mRNA and polysomal abundance in early 3T3-L1 adipogenesis.The Wnt/beta-catenin signaling pathway targets PPARgamma activity in colon cancer cellsA novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory responsePeroxisome proliferator-activated receptors in tumorigenesis: targets of tumour promotion and treatment.Insulin sensitiser drugs.PPARgamma Ligand as a Promising Candidate for Colorectal Cancer Chemoprevention: A Pilot Study.Gastrointestinal Cytoprotection by PPARγ Ligands.Small therapeutic molecules for the treatment of inflammatory bowel diseaseReview article: COX-2, prostanoids and colon cancer.Association between six genetic polymorphisms and colorectal cancer: a meta-analysis.Over-representation of PPARgamma sequence variants in sporadic cases of glioblastoma multiforme: preliminary evidence for common low penetrance modifiers for brain tumour risk in the general population.Cancer chemopreventive ability of conjugated linolenic acids.Activation of peroxisome proliferator-activated receptor gamma contributes to the survival of T lymphoma cells by affecting cellular metabolism.Effects of bacterial and presystemic nitroreductase metabolism of 2-chloro-5-nitro-N-phenylbenzamide on its mutagenicity and bioavailabilityReview article: the potential of combinational regimen with non-steroidal anti-inflammatory drugs in the chemoprevention of colorectal cancer.The effect of body weight on altered expression of nuclear receptors and cyclooxygenase-2 in human colorectal cancers.Anti- and Protumorigenic Effects of PPARγ in Lung Cancer Progression: A Double-Edged SwordThe role of peroxisome proliferator-activated receptors in colorectal cancer.Functional characterization of peroxisome proliferator-activated receptor-β/δ expression in colon cancer.The role of cyclooxygenase inhibition in the antineoplastic effects of nonsteroidal antiinflammatory drugs (NSAIDs)Peroxisome proliferator-activated receptor-γ activation enhances insulin-stimulated glucose disposal by reducing ped/pea-15 gene expression in skeletal muscle cells: evidence for involvement of activator protein-1Use of thiazolidinediones and the risk of colorectal cancer in patients with diabetes: a nationwide, population-based, case-control study.Cyclooxygenase 2 is up-regulated and localized to macrophages in the intestine of Min mice.Peroxisome proliferator-activated receptors and progression of colorectal cancer.Clinical Use of PPARgamma Ligands in Cancer.Thiazolidinedione therapy is not associated with increased colonic neoplasia risk in patients with diabetes mellitus.PPAR gamma signaling exacerbates mammary gland tumor development.Regulation of fatty acid homeostasis in cells: novel role of leptin.Space radiation exposure persistently increased leptin and IGF1 in serum and activated leptin-IGF1 signaling axis in mouse intestineCyclooxygenase-2 expression in the tumor environment is associated with poor prognosis in colorectal cancer patientsRole of peroxisome-proliferator-activated receptor beta/delta (PPARbeta/delta) in gastrointestinal tract function and diseaseTroglitazone Enhances the Apoptotic Response of DLD-1 Colon Cancer Cells to Photodynamic TherapyPotential of peroxisome proliferator-activated receptor gamma antagonist compounds as therapeutic agents for a wide range of cancer typesAdipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones
P2860
Q27687166-2F8F9FEA-ADB4-406B-AD50-1911FFB7DD10Q28238709-B00522E6-8D84-468A-95A9-AB2F4DD226D7Q33235601-1B98D17E-7720-4AC3-A8D4-1104E2FF965DQ33251021-29052D69-02B9-42E4-B2FB-302CBA566B1BQ33539473-E4D7D908-006A-4319-A9F5-F19EFBC34B3DQ33555154-C75103E0-0F83-4727-B315-406088EFC26FQ33691029-145A09FC-EBD3-416B-92A3-BB37298C2DA9Q33817896-DBEB7065-0C48-42CE-BA11-76EA40861A70Q33857617-ED0B3777-5AF4-413B-B31B-956E4A853597Q34007479-F42A3D2D-3117-4B15-B78C-9525CF624F75Q34074912-528B55B2-6C57-4A5A-BBB2-CB2EC7D2CD68Q34089258-78BB8866-75E3-4E57-BB36-2ADFDB92EFEEQ34159427-33955E98-CD7F-4852-B658-38A0F0DEA008Q34600992-1904DFC0-E706-47BD-968F-5D17FA880B0AQ34609415-9747B18A-33D7-40C2-8A66-613FD94122EAQ35098078-F7CFEF30-43B2-4934-AD68-68AADD1EA7D9Q35434987-25388EEE-C085-4114-80FA-E785F7DAA63BQ35600117-50F3C6CA-3715-47CC-86DE-28A01E74278DQ35750111-72B50A80-5877-469D-8598-39EF0C94F932Q35977641-7F39B0BC-EC28-47B9-915B-0CC3CFBC5CA6Q36041152-FF27EF78-4989-4BFD-9FC1-A93E0160B25CQ36059703-373B192A-7078-4775-98DC-2BAC2868E1F2Q36183887-63B66482-3479-45F2-A9A3-31BC69A35753Q36248494-189C2029-851B-4C9F-A50A-9DF34573CABAQ36352434-082EF526-E612-4A18-B80D-2E6D840CD8E1Q36375222-664E5B7D-39BE-41BA-998F-F8044F0268D8Q36466778-26016F2A-284C-4A9A-B469-F71CD4E49852Q36560240-1EB40D41-1914-4A38-B6BF-9095F4B6DA73Q36619181-746BC32F-B75B-410E-9811-FF9B76107F8CQ36710291-C142419D-C634-4896-801A-A03566FDA36AQ37021288-BC4DCF2B-176D-4DC1-A581-E81ADE8FCB9CQ37066317-6DF72B55-D161-4681-98B7-5B8A9AECD8B6Q37092279-255460C3-1DC0-416A-85EA-17DBC1C4429EQ37182555-0233200F-600D-4BE5-B592-EA61DCA3C19AQ37202378-02068BE5-D604-47D8-9564-4B855CA944AEQ37211803-A593A6D9-8BDB-4B03-9EB4-E4F0F750D3C8Q37212217-14046674-AFD0-4E1B-AAB9-91A87FEA6340Q37231914-66802D4F-3BA0-4AB6-A740-B9D7A79B9113Q37263875-9B424E03-0703-4D0B-BD44-F62EFCC1F94BQ37271252-D1FABA13-7729-4B2D-8C6D-6CDF96E112DA
P2860
The nuclear eicosanoid receptor, PPARgamma, is aberrantly expressed in colonic cancers
description
1998 nî lūn-bûn
@nan
1998 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
The nuclear eicosanoid receptor, PPARgamma, is aberrantly expressed in colonic cancers
@ast
The nuclear eicosanoid receptor, PPARgamma, is aberrantly expressed in colonic cancers
@en
The nuclear eicosanoid receptor, PPARgamma, is aberrantly expressed in colonic cancers
@nl
type
label
The nuclear eicosanoid receptor, PPARgamma, is aberrantly expressed in colonic cancers
@ast
The nuclear eicosanoid receptor, PPARgamma, is aberrantly expressed in colonic cancers
@en
The nuclear eicosanoid receptor, PPARgamma, is aberrantly expressed in colonic cancers
@nl
prefLabel
The nuclear eicosanoid receptor, PPARgamma, is aberrantly expressed in colonic cancers
@ast
The nuclear eicosanoid receptor, PPARgamma, is aberrantly expressed in colonic cancers
@en
The nuclear eicosanoid receptor, PPARgamma, is aberrantly expressed in colonic cancers
@nl
P2093
P3181
P356
P1433
P1476
The nuclear eicosanoid receptor, PPARgamma, is aberrantly expressed in colonic cancers
@en
P2093
P3181
P356
10.1093/CARCIN/19.1.49
P407
P577
1998-01-01T00:00:00Z